Published in J Clin Endocrinol Metab on November 01, 2002
Inflammation and insulin resistance. J Clin Invest (2006) 18.76
Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A (2009) 5.64
The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med (2012) 5.63
Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients (2013) 1.73
The STEDMAN project: biophysical, biochemical and metabolic effects of a behavioral weight loss intervention during weight loss, maintenance, and regain. OMICS (2009) 1.43
The immune system's involvement in obesity-driven type 2 diabetes. Semin Immunol (2013) 1.25
Subcutaneous adipose tissue macrophage infiltration is associated with hepatic and visceral fat deposition, hyperinsulinemia, and stimulation of NF-κB stress pathway. Diabetes (2011) 1.24
Uteroplacental insufficiency increases visceral adiposity and visceral adipose PPARgamma2 expression in male rat offspring prior to the onset of obesity. Early Hum Dev (2010) 1.17
Resveratrol improves adipose insulin signaling and reduces the inflammatory response in adipose tissue of rhesus monkeys on high-fat, high-sugar diet. Cell Metab (2013) 1.14
Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance. Cardiovasc Diabetol (2014) 1.09
The emerging use of zebrafish to model metabolic disease. Dis Model Mech (2013) 1.09
The role of the immune system in obesity and insulin resistance. J Obes (2013) 1.08
Visceral adiposity index, hypertriglyceridemic waist and risk of diabetes: the China Health and Nutrition Survey 2009. Int J Obes (Lond) (2013) 1.02
Location, location, location: Beneficial effects of autologous fat transplantation. Sci Rep (2011) 0.93
The relationship between the regional abdominal adipose tissue distribution and the serum uric acid levels in people with type 2 diabetes mellitus. Diabetol Metab Syndr (2012) 0.92
Transplantation or removal of intra-abdominal adipose tissue prevents age-induced glucose insensitivity. Physiol Behav (2010) 0.89
Common variations in perilipin gene, central obesity, and risk of type 2 diabetes in US women. Obesity (Silver Spring) (2008) 0.88
A protein profile of visceral adipose tissues linked to early pathogenesis of type 2 diabetes mellitus. Mol Cell Proteomics (2014) 0.88
Liver fat has a stronger association with risk factors for type 2 diabetes in African-American compared with Hispanic adolescents. J Clin Endocrinol Metab (2013) 0.86
Progression from high insulin resistance to type 2 diabetes does not entail additional visceral adipose tissue inflammation. PLoS One (2012) 0.86
Insulin sensitivity and regional fat gain in response to overfeeding. Obesity (Silver Spring) (2010) 0.84
Is visceral fat responsible for the metabolic abnormalities associated with obesity?: implications of omentectomy. Diabetes Care (2010) 0.83
Short-term regional meal fat storage in nonobese humans is not a predictor of long-term regional fat gain. Am J Physiol Endocrinol Metab (2012) 0.83
Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes. Vasc Health Risk Manag (2007) 0.82
Adaptive Immunity and Antigen-Specific Activation in Obesity-Associated Insulin Resistance. Mediators Inflamm (2015) 0.80
Abdominal visceral fat accumulation is associated with the results of (123)I-metaiodobenzylguanidine myocardial scintigraphy in type 2 diabetic patients. Eur J Nucl Med Mol Imaging (2007) 0.79
The cell size and distribution of adipocytes from subcutaneous and visceral fat is associated with type 2 diabetes mellitus in humans. Adipocyte (2015) 0.79
Aging Increases Susceptibility to High Fat Diet-Induced Metabolic Syndrome in C57BL/6 Mice: Improvement in Glycemic and Lipid Profile after Antioxidant Therapy. Oxid Med Cell Longev (2016) 0.78
IVGTT glucose minimal model covariate selection by nonlinear mixed-effects approach. Am J Physiol Endocrinol Metab (2010) 0.78
Fructooligosaccharide augments benefits of quercetin-3-O-β-glucoside on insulin sensitivity and plasma total cholesterol with promotion of flavonoid absorption in sucrose-fed rats. Eur J Nutr (2013) 0.78
Yi-Qi-Zeng-Min-Tang, a Chinese medicine, ameliorates insulin resistance in type 2 diabetic rats. World J Gastroenterol (2011) 0.78
Association between Abdominal Fat (DXA) and Its Subcomponents (CT Scan) before and after Weight Loss in Obese Postmenopausal Women: A MONET Study. J Obes (2011) 0.78
Differential Role of Adipose Tissues in Obesity and Related Metabolic and Vascular Complications. Int J Endocrinol (2016) 0.77
Effect of current glycemic control on qualitative body composition in sedentary ambulatory Type 2 diabetics. Niger Med J (2016) 0.77
Intrahepatic lipid, not visceral or muscle fat, is correlated with insulin resistance in older, female rhesus macaques. Obesity (Silver Spring) (2013) 0.77
Association of surrogate and direct measures of adiposity with risk of metabolic syndrome in rural Chinese women. Eur J Nutr (2009) 0.77
Plasma C5 glucose-to-2H2O ratio does not provide an accurate assessment of gluconeogenesis during hyperinsulinemic-euglycemic clamps in either nondiabetic or diabetic humans. Diabetes (2008) 0.77
Reduction of glucose intolerance with high fat feeding is associated with anti-inflammatory effects of thioredoxin 1 overexpression in mice. Pathobiol Aging Age Relat Dis (2012) 0.77
Serum Chemerin Levels Are Associated with Abdominal Visceral Fat in Type 2 Diabetes. J Korean Med Sci (2016) 0.77
Visceral fat area is associated with HbA1c but not dialysate-related glucose load in nondiabetic PD patients. Sci Rep (2015) 0.76
Fatty Liver and Insulin Resistance in the Liver-Specific Knockout Mice of Mitogen Inducible Gene-6. J Diabetes Res (2016) 0.75
Magnetic Resonance Imaging of Changes in Abdominal Compartments in Obese Diabetics during a Low-Calorie Weight-Loss Program. PLoS One (2016) 0.75
The influence of physical activity on risk of cardiovascular disease in people who are obese but metabolically healthy. PLoS One (2017) 0.75
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05
Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A (2003) 17.10
The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2005) 11.91
Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care (2007) 6.24
Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care (2006) 4.72
Nephropathy in diabetes. Diabetes Care (2004) 4.08
Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes (2006) 3.67
Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabetes Care (2007) 3.55
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest (2014) 3.31
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest (2014) 3.10
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY. Endocr Pract (2016) 3.01
Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab (2002) 2.98
alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS One (2010) 2.94
beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab (2004) 2.91
Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes (2004) 2.86
Common variants of the novel type 2 diabetes genes CDKAL1 and HHEX/IDE are associated with decreased pancreatic beta-cell function. Diabetes (2007) 2.73
What is the best predictor of future type 2 diabetes? Diabetes Care (2007) 2.64
Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab (2004) 2.59
Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care (2005) 2.53
Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology (2007) 2.50
Identification of individuals with insulin resistance using routine clinical measurements. Diabetes (2005) 2.46
Detailed physiologic characterization reveals diverse mechanisms for novel genetic Loci regulating glucose and insulin metabolism in humans. Diabetes (2010) 2.44
Visceral fat in hypertension: influence on insulin resistance and beta-cell function. Hypertension (2004) 2.33
Effect of acute exercise on AMPK signaling in skeletal muscle of subjects with type 2 diabetes: a time-course and dose-response study. Diabetes (2007) 2.26
Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. Diabetes (2011) 2.21
Thyroid disorders in chronic hepatitis C. Am J Med (2004) 2.19
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia (2015) 2.13
Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic nephropathy. Diabetes (2005) 2.12
Role of adiponectin in human skeletal muscle bioenergetics. Cell Metab (2006) 2.09
Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab (2002) 2.08
Peripheral disruption of the Grb10 gene enhances insulin signaling and sensitivity in vivo. Mol Cell Biol (2007) 2.08
Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. Diabetes (2002) 2.06
Physical activity and insulin sensitivity: the RISC study. Diabetes (2008) 2.03
Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes (2003) 2.02
Myocardial triglyceride content and epicardial fat mass in human obesity: relationship to left ventricular function and serum free fatty acid levels. J Clin Endocrinol Metab (2006) 1.98
Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes (2007) 1.96
Pathogenesis of insulin resistance in skeletal muscle. J Biomed Biotechnol (2010) 1.92
Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol (2007) 1.92
Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. Int J Cardiol (2011) 1.89
Metabolic syndrome: definition, pathophysiology, and mechanisms. Am Heart J (2005) 1.88
Diabetic nephropathy. Diabetes Care (2003) 1.87
Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes Care (2005) 1.83
Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia Study. Diabetes Care (2008) 1.81
Retinol-binding protein-4 in women with untreated essential hypertension. Am J Hypertens (2009) 1.76
Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients (2013) 1.73
Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology (2009) 1.71
Meal and oral glucose tests for assessment of beta -cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab (2002) 1.71
The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab (2007) 1.70
Lipid infusion decreases the expression of nuclear encoded mitochondrial genes and increases the expression of extracellular matrix genes in human skeletal muscle. J Biol Chem (2004) 1.69
Pathophysiology of prediabetes. Curr Diab Rep (2009) 1.67
Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab (2004) 1.67
Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab (2008) 1.67
Quantification of liver glucose metabolism by positron emission tomography: validation study in pigs. Gastroenterology (2006) 1.66
Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev (2006) 1.66
Obesity and type 2 diabetes: what can be unified and what needs to be individualized? J Clin Endocrinol Metab (2011) 1.63
Variation in the ADIPOQ gene promoter is associated with carotid intima media thickness independent of plasma adiponectin levels in healthy subjects. Eur Heart J (2007) 1.63
Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab (2003) 1.61
Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes. Hum Mol Genet (2009) 1.61
Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab (2004) 1.60
Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. Diabetes Care (2007) 1.57
Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients. Diabetes (2005) 1.57
Reduced time points to calculate the composite index. Diabetes Care (2010) 1.56
Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care (2013) 1.56
Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2008) 1.53
Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation. Diabetes (2002) 1.51
Association of the gene encoding wingless-type mammary tumor virus integration-site family member 5B (WNT5B) with type 2 diabetes. Am J Hum Genet (2004) 1.49
Pancreatic islet amyloidosis, beta-cell apoptosis, and alpha-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons. Proc Natl Acad Sci U S A (2009) 1.45
Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab (2006) 1.44
Pattern of expression of inflammatory markers in adipose tissue of untreated hypertensive patients. J Hypertens (2010) 1.43
Human insulin resistance is associated with increased plasma levels of 12α-hydroxylated bile acids. Diabetes (2013) 1.41
Reduced skeletal muscle inhibitor of kappaB beta content is associated with insulin resistance in subjects with type 2 diabetes: reversal by exercise training. Diabetes (2006) 1.41
Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab (2006) 1.41
Does reduced IGF-1R signaling in Igf1r+/- mice alter aging? PLoS One (2011) 1.39
Visceral fat dominant distribution in male type 2 diabetic patients is closely related to hepatic insulin resistance, irrespective of body type. Cardiovasc Diabetol (2009) 1.38
Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes (2012) 1.38
The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance. Am J Physiol Endocrinol Metab (2008) 1.37
Physiological and molecular determinants of insulin action in the baboon. Diabetes (2008) 1.34
Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care (2007) 1.32
Obesity and type 2 diabetes: what can be unified and what needs to be individualized? Diabetes Care (2011) 1.31
Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes. J Clin Endocrinol Metab (2004) 1.31
Mitochondrial dysfunction, insulin resistance, and type 2 diabetes mellitus. Curr Diab Rep (2008) 1.31
Low-grade systemic inflammation causes endothelial dysfunction in patients with Hashimoto's thyroiditis. J Clin Endocrinol Metab (2006) 1.29